What clinical trials has Neurocept completed for depression through 2023?

1. What claim is being tested — and where the confusion starts!

The core claim examined is whether Neurocept completed clinical trials for depression through 2023. The dataset contains a ClinicalTrials.gov record for a study of oral NMRA‑335140 in Major Depressive Disorder, described as assessing effects in participants ^[1]. Separate items reference Neumora Therapeutics’ navacaprant Phase 2/Phase 3 activity and other depression trial summaries ^{[2] [3]}. At the same time, product information for a medication named “Neurocept‑PG Capsule” focuses exclusively on neuropathic pain and epilepsy indications, with no depression trials listed ^{[4] [5]}. This mix of trial registry entries, company names, and a marketed product creates multiple possible sources of mistaken identity.

2. What the ClinicalTrials.gov entry actually says — direct reading of the registry

The ClinicalTrials.gov entry included in the dataset reports a study titled “Study to Assess the Effects of Oral NMRA‑335140 in Participants With Major Depressive Disorder,” and is presented as a trial record relevant to depression ^[1]. The record in the dataset does not, however, provide an unambiguous attribution to Neurocept as sponsor or confirm completion through 2023; the analysis notes the completion status and results are not explicitly stated in the provided text ^[1]. In short, the registry entry exists but does not prove Neurocept completed the trial by 2023, according to the supplied analysis. The record therefore raises a possibility but not a confirmed fact.

3. Who else appears in the supplied evidence — similar names and late‑stage programs

Multiple supplied analyses point to Neumora Therapeutics (formerly BlackThorn) conducting depression trials, including a Phase 2 trial of navacaprant that reported statistically significant results and plans for Phase 3 ^{[2] [3]}. One of the dataset entries explicitly identifies Neumora, not Neurocept, as the sponsor of an NMRA‑335140 study ^[6]. This indicates an alternative, more documentable pathway for the depression trials mentioned: Neumora’s program, not Neurocept’s, and suggests that the presence of NMRA‑335140/related identifiers in the dataset may have been conflated across company names. The product pages for Neurocept‑PG in the dataset concern neuropathic pain and epilepsy, further distancing Neurocept from the depression studies ^{[4] [5]}.

4. What the available evidence omits — why the claim cannot be supported

The supplied materials lack an authoritative Neurocept corporate disclosure, peer‑reviewed trial publication, or a ClinicalTrials.gov record explicitly naming Neurocept as the sponsor with a completed status through 2023. The ClinicalTrials.gov entry in the dataset does not state completion or outcomes tied to Neurocept ^[1], and product listings for Neurocept‑PG show indications unrelated to depression ^{[4] [5]}. Systematic analyses of depression trials included in the dataset aggregate thousands of trials worldwide but do not single out Neurocept as a completed depression trial sponsor ^[7]. Taken together, the absence of direct sponsorship attribution, completion dates, and results in the supplied sources means the claim is unproven on the evidence provided.

5. Bottom line and next steps for verification — how to resolve the ambiguity

Based on the supplied analyses, do not accept the statement that Neurocept completed depression trials through 2023; the evidence instead suggests trial activity by other companies (notably Neumora) and product information for Neurocept that does not involve depression ^{[2] [3] [4]}. To resolve this definitively, consult primary sources: the full ClinicalTrials.gov record^[8] for NMRA‑335140, Neurocept corporate filings or press releases, and peer‑reviewed trial reports. The dataset shows plausible conflation and incomplete attribution between similarly named actors; further primary-document checks are required to move from uncertainty to confirmation ^{[1] [6] [3]}.